• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
      • Contact Us
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
    • Research & Development
      • Etripamil
      • Publications
      • Clinical Trials
      • Patient Access
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
Close
0
  • Milestone Pharma

Long-Term Outcomes of the NODE-302 Study. In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.

  • October 3, 2022
  • Publication
  • By Debbie Everidge
  • 0 Comments
Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use
© Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
  • English: United States
    • English: Canada
    • Français (French): Canada

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

  • English: United States
  • English: Canada
  • Français (French): Canada